Dicerna Pharmaceuticals, which is developing RNAi therapeutics for the treatment of rare liver disease and cancer, raised $90 million by offering 6.0 million shares at $15.00, above expectations. Dicerna Pharmaceuticals plans to list on the NASDAQ under the symbol DRNA. Dicerna Pharmaceuticals initially filed confidentially on 11/8/2013. Jefferies & Co., Leerink Partners and Stifel acted as joint bookrunners on the deal.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.